StreetInsider.com News Articles

B.Riley Reiterates Buy Rating on Journey Medical Corp. (DERM)

Wed, 04 Feb 2026 06:49:03 -0500

B.Riley analyst Kalpit Patel reiterated a Buy rating and $12.00 price target on Journey Medical Corp. (NASDAQ: DERM).

The analyst comments "The IQVIA weekly sales data for EMROSI shows continued commercial momentum, with weekly TRx reaching a peak of ~2.5k in early January before moderating to ~1.9k in the most recent week, consistent with typical postholiday seasonality patterns (Exhibit 10). NRx has similarly moderated to ~850 from ~1k, maintaining the refill ratio near ~1.2:1, supportive of management's expectation of 3-4 refills annually and indicative of real-world patient adherence. The single ANDA filing against EMROSI disclosed 1/27 is viewed as a non-event,

Form 424B3 Journey Medical Corp

Fri, 23 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260123/25887093.html

Form 424B3 Journey Medical Corp

Fri, 23 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260123/25887093.html

Form 424B3 Journey Medical Corp

Fri, 23 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260123/25887116.html

Form 424B3 Journey Medical Corp

Fri, 23 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260123/25887116.html

Form EFFECT Journey Medical Corp

Thu, 22 Jan 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260122/25877723.html

Form EFFECT Journey Medical Corp

Thu, 22 Jan 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260122/25877723.html

Journey Medical Corp (DERM) files $150M mixed shelf

Thu, 15 Jan 2026 16:45:48 -0500

Journey Medical Corp (NASDAQ: DERM) has filed $150,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

DEBT SECURITIES

WARRANTS

UNITS

Journey Medical Corp (DERM) files $150M mixed shelf

Thu, 15 Jan 2026 16:45:48 -0500

Journey Medical Corp (NASDAQ: DERM) has filed $150,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

DEBT SECURITIES

WARRANTS

UNITS

Form S-3 Journey Medical Corp

Thu, 15 Jan 2026 16:44:00 -0500

si-local-file:///var/storage/secattach/20260115/25856175.html

Form S-3 Journey Medical Corp

Thu, 15 Jan 2026 16:44:00 -0500

si-local-file:///var/storage/secattach/20260115/25856175.html

Journey Medical publishes Emrosi clinical trial results in dermatology journal

Wed, 10 Dec 2025 08:30:26 -0500

Journey Medical Corporation (NASDAQ: DERM) announced that results from a Phase 1 clinical trial evaluating its rosacea treatment Emrosi were published in the Journal of Drugs in Dermatology. The study assessed the drug's impact on microbial flora in healthy adults over 16 weeks.

The multicenter, randomized, double-blind, placebo-controlled trial enrolled 60 healthy adults in a 2:1 randomization between Emrosi and placebo. Participants received once-daily oral treatment for 16 weeks while microbiological samples were collected from skin, stool and vaginal sites.

The study achieved its three primary endpoints: no significant change in normal microbiome of skin, vagina or gastrointestinal tract; no development of

Journey Medical publishes Emrosi clinical trial results in dermatology journal

Wed, 10 Dec 2025 08:30:26 -0500

The study achieved its three primary endpoints: no significant change in normal microbiome of skin, vagina or gastrointestinal tract; no development of

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Wed, 10 Dec 2025 08:30:00 -0500